Insightec said it has received market approval for its Exablate 4000 (Neuro) platform from the National Health Surveillance Agency (ANVISA) in Brazil. Designed as a treatment for essential tremor and tremor-dominant Parkinson's Disease that has not responded to medications and neuropathic pain, Exablate Neuro provides MR-guided focused ultrasound to ablate tissue deep in the brain, according to the company.